The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. Synthetic Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. 7 Water Stocks to Buy as the World Dries Up.7 Solar Stocks Leading the Clean Energy Boom.7 Railroad Stocks to Keep Your Portfolio Chugging Along.7 Agricultural Stocks to Buy to Keep Your Portfolio Well Fed.7 Streaming Stocks that Will Stand up to Streaming Fatigue.7 Cash Rich Stocks That Offer Safety in Any Market.7 Small-Cap Stocks That Could Rocket Higher in 2023.7 Most Overhyped Penny Stocks to Sell Now.7 Stocks to Buy During a Housing Downturn.After a $100 Haircut, is Catalent an Oversold Pharma Play?.Is It Time To Take A Ride With Joby Aviation’s EV Innovations?.This Mid-Cap Tech Stock Embodies Diversified Growth.Why did NIO take a $581.11 million loss last quarter?.
#Syn stock price software#
Take Two Interactive Software Stock is Taking One Step Back.Wayfair Still Has Its Fair Share of Issues.Agilent Remains In Buy Range Ahead Of Next Week's Q4 Report.Three Penny Stocks Making Big Moves In November.Don’t Chase Walmart Higher, Wait For Extra Low Prices.The Trader's Guide to Equities Research.
0 kommentar(er)
